Our library of clinical trials information is updated regularly from the US government database on clinical trials, so you can be assured that new zofran clinical trials listings will be included here shortly after becoming available to us.
Related Sponsors
Clinical Trials on zofran
- A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)
Status: Active, not recruiting, Condition Summary: Postoperative Nausea and Vomiting - Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Status: Recruiting, Condition Summary: Chemotherapy Induced Nausea and Vomiting - Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting
Status: Recruiting, Condition Summary: Postoperative Nausea and Vomiting - Effect of Ondansetron for Withdrawal Symptoms
Status: Enrolling by invitation, Condition Summary: Substance Withdrawal Syndrome - A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Status: Recruiting, Condition Summary: Colorectal Cancer - Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration
Status: Not yet recruiting, Condition Summary: Dehydration; Gastroenteritis - New Medication Treatment for Stimulant Dependence
Status: Not yet recruiting, Condition Summary: Cocaine Dependence - Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial
Status: Completed, Condition Summary: Alcohol Dependence - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Status: Completed, Condition Summary: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Nausea and Vomiting; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific - Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen
Status: Active, not recruiting, Condition Summary: Cancer - Dexamethasone and Ondansetron or Palonosetron in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy for Early-Stage Breast Cancer
Status: Recruiting, Condition Summary: Breast Cancer; Nausea and Vomiting - Aprepitant, Ondansetron, and Dexamethasone in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
Status: Active, not recruiting, Condition Summary: Cancer - Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Status: Completed, Condition Summary: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific - Effect of Acupuncture on Postoperative Nausea and Vomiting
Status: Completed, Condition Summary: Cholelithiasis - Pharmacotherapy for HIV+ Stimulant Dependent Individuals
Status: Recruiting, Condition Summary: HIV Infections; Cocaine Dependence - Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
Status: Recruiting, Condition Summary: Tumor - POWS: Palonosetron/Ondansetron Opioid Withdrawal Study
Status: Recruiting, Condition Summary: Substance-Related Disorders - Effectiveness of Aprepitant in the Treatment of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Outpatient Plastic Surgery
Status: Not yet recruiting, Condition Summary: Postoperative Nausea and Vomiting (PONV) - Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions
Status: Completed, Condition Summary: Healthy - Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions
Status: Completed, Condition Summary: Healthy - Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions
Status: Completed, Condition Summary: Healthy - Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions
Status: Completed, Condition Summary: Healthy - Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED
Status: Recruiting, Condition Summary: Nausea - Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg
Status: Completed, Condition Summary: Healthy - Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg
Status: Completed, Condition Summary: Healthy - Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
Status: Completed, Condition Summary: Healthy - Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Status: Completed, Condition Summary: Chemotherapy Induced Nausea and Vomiting - Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
Status: Completed, Condition Summary: Healthy - A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
Status: Completed, Condition Summary: Nausea; Vomiting - Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
Status: Completed, Condition Summary: Nausea; Vomiting